Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
出版年份 2023 全文链接
标题
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
作者
关键词
-
出版物
Frontiers in Endocrinology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-06-26
DOI
10.3389/fendo.2023.1176731
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
- (2023) Xiao Zhao et al. THYROID
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
- (2022) V. Subbiah et al. ANNALS OF ONCOLOGY
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors
- (2022) George D. Demetri et al. CLINICAL CANCER RESEARCH
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
- (2022) Vicky Makker et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer
- (2022) S. Filetti et al. ANNALS OF ONCOLOGY
- Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
- (2022) Steven G Waguespack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
- (2022) Manuel Weber et al. CLINICAL CANCER RESEARCH
- Phase 2 of trametinib plus radioiodine in RAS-mutant and wild-type, radioiodine-refractory thyroid cancer (ETCTN9446).
- (2022) Bharat Burman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
- (2022) Aaron Scott Mansfield et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial
- (2022) Naifa L. Busaidy et al. THYROID
- Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial
- (2022) Marcia S. Brose et al. CANCER
- Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers
- (2022) Marie-Claude Hofmann et al. ENDOCRINE-RELATED CANCER
- Adherens Junction Integrity Is a Critical Determinant of Sodium Iodide Symporter Residency at the Plasma Membrane of Thyroid Cells
- (2022) Márcia Faria et al. Cancers
- Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
- (2022) Jing Ding et al. Experimental Hematology & Oncology
- Reversing “Flip-Flop” Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib
- (2022) Hung-Pin Chan et al. CLINICAL NUCLEAR MEDICINE
- Diagnostics, Therapeutics and RET Inhibitor Resistance for RET Fusion–Positive Non-Small Cell Lung Cancers and Future Perspectives
- (2021) Chang Lu et al. CANCER TREATMENT REVIEWS
- Redifferentiation-facilitated radioiodine therapy in thyroid cancer
- (2021) Livia Lamartina et al. ENDOCRINE-RELATED CANCER
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
- (2021) Sara Fancelli et al. Cancers
- CAR-T cells and BiTEs in solid tumors: challenges and perspectives
- (2021) Julien Edeline et al. Journal of Hematology & Oncology
- NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis
- (2021) Barbora Pekova et al. Cancers
- Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E-Driven Papillary Thyroid Cancer Patients
- (2021) Theodora Pappa et al. CLINICAL CANCER RESEARCH
- Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights
- (2021) Asumi Iesato et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).
- (2021) Eric Jeffrey Sherman et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- (2021) Vivek Subbiah et al. Lancet Diabetes & Endocrinology
- CAR-T Cells Targeting TSHR Demonstrate Safety and Potent Preclinical Activity Against Differentiated Thyroid Cancer
- (2021) Hanning Li et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer
- (2021) Andrée Boucher et al. ORAL ONCOLOGY
- RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient
- (2021) Rozita Bagheri-Yarmand et al. Cancers
- RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
- (2020) Benjamin J. Solomon et al. Journal of Thoracic Oncology
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Advances in Targeting RET-Dependent Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- Redifferentiation of radioiodine-refractory thyroid cancers
- (2020) Camille Buffet et al. ENDOCRINE-RELATED CANCER
- THERAPY OF ENDOCRINE DISEASE: Immunotherapy of advanced thyroid cancer: from bench to bedside
- (2020) Sonia Moretti et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
- (2020) Bryan Haugen et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).
- (2020) Jochen H. Lorch et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC)
- (2020) Ying-Hsia Chu et al. MODERN PATHOLOGY
- Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
- (2020) Maria E. Cabanillas et al. THYROID
- A phase 1b/2 study of the BRAF inhibitor encorafenib plus the MEK inhibitor binimetinib in patients with BRAF V600E/K-mutant solid tumors
- (2020) Ryan J. Sullivan et al. CLINICAL CANCER RESEARCH
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
- (2020) April K. S. Salama et al. JOURNAL OF CLINICAL ONCOLOGY
- An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
- (2020) Keith C. Bible et al. THYROID
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
- (2020) Lori J. Wirth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer
- (2020) Lionel Groussin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer
- (2020) Carlotta Giani et al. THYROID
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
- (2019) Salvatore Ulisse et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
- (2019) Janice M. Mehnert et al. BMC CANCER
- Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma
- (2019) Jennifer Rui Wang et al. THYROID
- Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
- (2019) Maria E Cabanillas et al. ENDOCRINE REVIEWS
- The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts the Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
- (2019) Jiajun Liu et al. JOURNAL OF NUCLEAR MEDICINE
- Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies
- (2019) Mohamed Aashiq et al. Cancers
- Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake
- (2019) Alice Fletcher et al. CANCER RESEARCH
- Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol
- (2019) Amir Iravani et al. THYROID
- Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
- (2019) Carla Fernanda Nava et al. Frontiers in Endocrinology
- Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance
- (2019) Husain Yar Khan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study
- (2018) Glenn J. Hanna et al. CLINICAL CANCER RESEARCH
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine
- (2018) Tania Jaber et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin
- (2018) Min Liu et al. Scientific Reports
- Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma
- (2018) Raj K. Gopal et al. CANCER CELL
- Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
- (2018) Lara A Dunn et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
- (2017) Alain Ravaud et al. EUROPEAN JOURNAL OF CANCER
- Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)
- (2017) Jaume Capdevila et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
- (2017) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
- (2017) Alexander Drilon et al. Nature Reviews Clinical Oncology
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Everolimus in patients with advanced follicular-derived thyroid cancer; results of a phase II clinical trial.
- (2016) T.C. Schneider et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Thyroid cancer
- (2016) Maria E Cabanillas et al. LANCET
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- (2016) Marcia S Brose et al. LANCET ONCOLOGY
- Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence
- (2016) Sales Ibiza et al. NATURE
- Epithelial–mesenchymal transition: a new target in anticancer drug discovery
- (2016) Fabrizio Marcucci et al. NATURE REVIEWS DRUG DISCOVERY
- Biologic and Clinical Perspectives on Thyroid Cancer
- (2016) James A. Fagin et al. NEW ENGLAND JOURNAL OF MEDICINE
- ROS1Rearrangement in Thyroid Cancer
- (2016) Lauren L. Ritterhouse et al. THYROID
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model
- (2016) Brian P. Danysh et al. Oncotarget
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib--Response
- (2015) S. M. Rothenberg et al. CLINICAL CANCER RESEARCH
- An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer
- (2015) Sun Min Lim et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer
- (2015) Athanasios Bikas et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- BRAF Inhibitor Dabrafenib in Patients with MetastaticBRAF-Mutant Thyroid Cancer
- (2015) Gerald S. Falchook et al. THYROID
- Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model
- (2015) Mark Duquette et al. Oncotarget
- PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
- (2015) J. J. Severson et al. Cancer Immunology Research
- Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments
- (2014) Laura D. Locati et al. CANCER
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma
- (2014) Nishant Agrawal et al. CELL
- MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
- (2014) T. E. Angell et al. CLINICAL CANCER RESEARCH
- TERTPromoter Mutations and Their Association withBRAFV600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer
- (2014) Xiaoli Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function
- (2014) Diogo Fonseca-Pereira et al. NATURE
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes
- (2013) S. M. Lim et al. ANNALS OF ONCOLOGY
- Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy
- (2013) Ian Ganly et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
- (2013) Kevin B. Kim et al. THYROID
- Programmed Death-1+T Cells and Regulatory T Cells Are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Features in Papillary Thyroid Cancer
- (2012) Jena D. French et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
- (2011) Debyani Chakravarty et al. JOURNAL OF CLINICAL INVESTIGATION
- HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
- (2010) F. Shojaei et al. CANCER RESEARCH
- Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation
- (2010) L. L. Carr et al. CLINICAL CANCER RESEARCH
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
- (2010) Mingzhao Xing THYROID
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started